文献速递生殖医学产科母胎医学

美国首例 deceased donor 子宫移植活产:从严重排斥到剖宫产

First birth from a deceased donor uterus in the United States: from severe graft rejection to successful cesarean delivery.
PubMed 文献 · Am J Obstet Gynecol · 2020-03-07

本文报告美国首例 deceased donor 子宫移植后活产:35岁先天性无子宫女性接受24岁 deceased donor 子宫,移植后6个月出现 grade 3 混合性排斥,经靶向细胞与体液免疫治疗3个月后排斥清除,胚胎移植后妊娠,21周诊断中央性前置胎盘伴植入,34周行剖宫产子宫切除分娩健康新生儿。

要点

  • deceased donor 子宫移植后 severe mixed cellular/humoral rejection 可逆,且仍可获得活产。
  • 排斥清除后3个月再行胚胎移植,妊娠21周诊断中央性前置胎盘伴植入。
  • 34周剖宫产子宫切除分娩健康新生儿,为 North America 首例 deceased donor 子宫移植活产。

核心结论

  • deceased donor 子宫移植后发生严重 prolonged rejection 仍可恢复并分娩健康新生儿。
  • 本例为 North America 首例 deceased donor 子宫移植活产。

研究设计与样本

  • Cleveland Clinic 子宫移植临床试验于2015年开放,本文报告其中首例分娩。
  • 受者为35岁先天性无子宫女性,供者为24岁经产 deceased brain-dead donor。

主要发现

  • 移植术式包括阴道吻合及供者双侧 internal iliac vessels 与受者 external iliac vessels 血管吻合。
  • 移植后6个月计划妊娠前 ectocervical biopsy 示溃疡及弥漫性浆细胞丰富混合炎性细胞浸润,判为 grade 3 rejection 并疑抗体介导成分。
  • 针对细胞与体液排斥的强化免疫抑制治疗3个月后组织学无排斥证据。
  • 排斥完全清除后3个月行胚胎移植并建立妊娠。
  • 妊娠21周诊断中央性前置胎盘伴植入,34周剖宫产子宫切除分娩健康新生儿。

关键数值与推荐

  • 排斥组织学为 grade 3 rejection,伴弥漫性浆细胞丰富混合炎性细胞浸润及溃疡。
  • 强化免疫抑制治疗3个月后组织学排斥清除,再3个月后行胚胎移植。
  • 妊娠21周诊断中央性前置胎盘伴植入,34周行剖宫产子宫切除。

临床怎么用

  • 子宫移植受者孕前需经 ectocervical biopsy 确认排斥清除后再行胚胎移植。
  • 妊娠期应警惕前置胎盘伴植入,并计划于适当孕周行剖宫产子宫切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uterus transplantation is the only known potential treatment for absolute uterine factor infertility. It offers a unique setting for the investigation of immunologic adaptations of pregnancy in the context of the pharmacologic-induced tolerance of solid organ transplants, thus providing valuable insights into the early maternal-fetal interface. Until recently, all live births resulting from uterus transplantation involved living donors, with only 1 prior birth from a deceased donor. The Cleveland Clinic clinical trial of uterus transplantation opened in 2015. In 2017, a 35 year old woman with congenital absence of the uterus was matched to a 24 year old parous deceased brain-dead donor. Transplantation of the uterus was performed with vaginal anastomosis and vascular anastomoses bilaterally from internal iliac vessels of the donor to the external iliac vessels of the recipient. Induction and maintenance immunosuppression were achieved and subsequently modified in anticipation of pregnancy 6 months after transplant. Prior to planned embryo transfer, ectocervical biopsy revealed ulceration and a significant diffuse, plasma cell-rich mixed inflammatory cell infiltrate, with histology interpreted as grade 3 rejection suspicious for an antibody-mediated component. Aggressive immunosuppressive regimen targeting both cellular and humoral rejection was initiated. After 3 months of treatment, there was no histologic evidence of rejection, and after 3 months from complete clearance of rejection, an uneventful embryo transfer was performed and a pregnancy was established. At 21 weeks, central placenta previa with accreta was diagnosed. A healthy neonate was delivered by cesarean hysterectomy at 34 weeks' gestation. In summary, this paper highlights the first live birth in North America resulting from a deceased donor uterus transplant. This achievement underscores the capacity of the transplanted uterus to recover from a severe, prolonged rejection and yet produce a viable neonate. This is the first delivery from our ongoing clinical trial in uterus transplantation, including the first reported incidence of severe mixed cellular/humoral rejection as well as the first reported placenta accreta.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Flyckt R, Falcone T, Quintini C, et al. First birth from a deceased donor uterus in the United States: from severe graft rejection to successful cesarean delivery. Am J Obstet Gynecol. 2020. PMID: 32151611. doi:10.1016/j.ajog.2020.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。